Results 11 to 20 of about 12,616 (217)

MiR-18a-5p attenuates HER2-positive breast cancer development by regulating PI3K/AKT pathway

Cancer Biology & Therapy, 2023
Objective: Human epidermal growth factor receptor 2 positive (HER2+) breast cancer (BC) is associated with poor prognosis. This study aimed to elucidate the role of miR−18a−5p in regulation of HER2+-BC progression along with its mechanism of action ...
Yongjun Liu, Hua Yang
doaj   +1 more source

Calmodulin binds HER2 and modulates HER2 signaling

Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2011
Human epidermal growth factor receptor 2 (HER2), a member of the ErbB family of receptor tyrosine kinases, has defined roles in neoplastic transformation and tumor progression. Overexpression of HER2 is an adverse prognostic factor in several human neoplasms and, particularly in breast cancer, correlates strongly with a decrease in overall patient ...
White, Colin D., Li, Zhigang, Sacks, David B.   +2 more
openaire   +2 more sources

Loss of Nuclear ARID-1A Expressions Is Associated with Hormone Receptor Status in Breast Cancers

European Journal of Breast Health, 2019
Objective:Breast cancer is the most common cancer among women worldwide. Adenine thymine-rich interactive domain 1A (ARIDIA) is a tumor suppressor gene involved in chromatin remodeling and it encodes the ARIDIA protein. Recent studies have shown the loss
Melek Ünçel, Gülden Diniz, Gamze Aköz, Zübeyde Yıldırım Ekin, Sevil Sayhan, Serdar Yardım, Semra Salimoğlu   +6 more
doaj   +1 more source

Pattern of HER2 Overexpression in Urinary Bladder Carcinomas in Kano, Nigeria

The Annals of African Surgery, 2023
Background: The worldwide distribution of bladder cancer varies, conforming to differences in environmental and genetic risk factors. HER2 neu is overexpressed in many human cancers, including urinary bladder carcinomas.
Muhammad Sanusi Haruna, Akinfenwa Taoheed Atanda, Yawale Iliyasu   +2 more
doaj   +1 more source

Indian Data on HER2 Fluorescence In Situ Hybridization in Invasive Breast Cancer with Immunohistochemically Equivocal Results As Per 2018 ASCO/CAP Guidelines

South Asian Journal of Cancer, 2022
Biren Parikh Introduction Hormonal status and HER2 expression are valuable biomarkers and dictate the management of the patients diagnosed with invasive breast cancer (IBC).
B. R. Nagarjun, Biren Parikh, Manaswi Nareshkumar Patel, Pina J. Trivedi, Dharmesh M. Patel   +4 more
doaj   +1 more source

[18F]FDG PET/CT volumetric biomarkers for non-invasive prediction of HER2 expression in breast cancer patients [PDF]

Asia Oceania Journal of Nuclear Medicine and Biology
Objective(s): to investigate the capability of 18F-fluorodeoxyglucose positron emission tomography/computed tomography ([18F]-FDG PET/CT) derived volumetric parameters to predict human epidermal growth factor receptor 2 (HER2) status in breast cancer ...
Mai ELahmadawy, Heba Abdelhameed, Dina Gamal El-din, Mahitab Eltohamy, Adel Hassan, Salwa Abd El-Gaid   +5 more
doaj   +1 more source

Insulin receptor substrate 4 (IRS4) is a constitutive active oncogenic driver collaborating with HER2 and causing therapeutic resistance

Molecular & Cellular Oncology, 2017
Insulin receptor substrate 4 (IRS4) belongs to a family of cytoplasmic docking proteins mediating signals from cell surface receptors to downstream effectors.
Gerjon J. Ikink, John Hilkens
doaj   +1 more source

HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer [PDF]

American Journal of Clinical Pathology, 2017
Approximately 15% of breast cancers show equivocal human epidermal growth factor receptor 2 (HER2) results on HER2 immunohistochemistry (IHC) and are reflexed for fluorescence in situ hybridization (FISH). However, some cases remain equivocal. In this study, we evaluated these double-equivocal cases by using a novel gene protein assay (GPA), which can ...
Yanjun, Hou, Hiroaki, Nitta, Zaibo, Li
openaire   +2 more sources

Cardiac Safety of Trastuzumab on 185 Patients with HER2 Positive Breast Cancer

Zhongliu Fangzhi Yanjiu, 2018
Objective To analyze the cardiac safety of trastuzumab on HER2 positive breast cancer patients. Methods Trastuzumab was administrated every three weeks in 185 patients with HER2 positive breast cancer.
MENG Wenjing, ZHANG Jibo, LI Shufen, TONG Zhongsheng   +3 more
doaj   +1 more source

Anti‐proliferative effects of pentagamaboronon‐0‐sorbitol on HER2‐overexpressing breast cancer cells

Indonesian Journal of Biotechnology, 2022
HER2‐positive breast cancer is an aggressive form of the disease that is associated with poor prognosis and chemo‐resistance. As such, investigation continues into the development of a new HER2‐targeted drug for breast cancer. This study investigated the
Lailatul Qodria, Rohmad Yudi Utomo, Adam Hermawan, Edy Meiyanto   +3 more
doaj   +1 more source